Streetbeat News

Earnings

BMRN

PTCT

PTC Therapeutics Inc (PTCT) reported a delay in the planned submission of sepiapterin in phenylketonuria (PKU) in its Q3 earnings release. The FDA has pushed the timeline for FDA approval, requiring a 26-week nonclinical mouse study before seeking authorization. This delay will push the filing for FDA approval to the third quarter of next year. PTCT shares are down 22.40% at $18.60 on the last check Friday.

Portfolio Pulse from Vandana Singh

October 27, 2023 | 5:00 pm

APPF

AppFolio's shares are trading higher following the company's Q3 financial results, which exceeded expectations.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:58 pm

BIO

Bio-Rad Laboratories reported worse-than-expected Q3 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:58 pm

AX

Axos Financial reported its Q1 financial results, which led to a decrease in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:51 pm

SAM

Boston Beer's shares are trading lower following the release of its Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:50 pm

FIX

Comfort Systems USA has reported its Q3 financial results and announced a dividend increase, leading to a rise in its share price.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:50 pm

EXPO

Exponent shares are trading lower following the company's mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:47 pm

ARCB

ArcBest reported mixed Q3 financial results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:46 pm

KNSL

Kinsale Capital's shares are trading lower following the release of the company's mixed Q3 financial results.

Portfolio Pulse from Benzinga Newsdesk

October 27, 2023 | 4:38 pm

SWI

SolarWinds Corp (NYSE:SWI) is reportedly exploring options for a potential sale, causing its stock to trade higher. The software provider, controlled by Silver Lake Management and Thoma Bravo, is expected to kick off the sale process in early 2024. In Q2 FY23, SolarWinds reported a 5% YoY revenue growth to $185 million, beating the consensus of $179.5 million. The company expects FY23 revenue to be $740 million - $748 million.

Portfolio Pulse from Anusuya Lahiri

October 27, 2023 | 4:34 pm